High Frequency of Nonadherence to Clostridium difficile Treatment Guidelines
| Autor: | Nitin Bhanot, M. Catherine McEllistrem, Raktima Goswami, Andrew G. Sahud, Noreen H. Chan-Tompkins, Molly McGraw |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Antibiotics Severe disease Disease Severity of Illness Index Vancomycin Metronidazole Internal medicine Health care Epidemiology Humans Medicine Retrospective Studies Clostridioides difficile business.industry Patient Selection General Medicine Clostridium difficile Decision Support Systems Clinical Anti-Bacterial Agents Regimen Practice Guidelines as Topic Clostridium Infections Critical Pathways Guideline Adherence business medicine.drug |
| Zdroj: | Southern Medical Journal. 107:597-599 |
| ISSN: | 0038-4348 |
| DOI: | 10.14423/smj.0000000000000167 |
| Popis: | OBJECTIVES The 2010 Infectious Diseases Society of America/Society for Healthcare Epidemiology of America treatment guidelines for Clostridium difficile infections (CDI) recommend oral metronidazole for mild-to-moderate disease and oral vancomycin for severe disease. Given that disease severity is easily determined by the peripheral white blood cell count and serum creatinine level, a computerized decision support (CDS) pathway to guide treatment is inherently appealing. Because providers often override or ignore the computer-based alerts, the proposed CDS pathway should be justified before implementation. METHODS We undertook this study to ascertain the frequency of nonadherence to CDI guidelines. Between October 1, 2007 and September 30, 2008, a total of 229 cases were screened and 78 cases were included in the study, which took place at a 661-bed acute tertiary care teaching hospital. RESULTS During the year-long study of CDI cases at our tertiary care hospital, 61.5% (48/78) of the patients received an antibiotic regimen that was not recommended by the 2010 guidelines. Among the 35 patients with mild-to-moderate CDI, 85.7% (30/35) received the recommended treatment of oral metronidazole monotherapy; in contrast, among the 43 patients with severe disease, none (0/43) received the recommended treatment of oral vancomycin monotherapy (P < 0.01). Moreover, 17.9% (14/78) of patients received concurrent oral metronidazole and vancomycin, a regimen that is not recommended anywhere in the Infectious Diseases Society of America/Society for Healthcare Epidemiology of America guidelines and which may be associated with a poor outcome. Patients who received combination oral metronidazole and vancomycin were not more likely to have comorbidities or severe CDI compared with those who received a single antibiotic agent. CONCLUSIONS As a result of this study, we plan to educate our providers on the treatment of CDI through a CDS pathway in an effort to increase guideline adherence, decrease inappropriate antibiotic use, and potentially improve patient outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|